Mendelian traits that confer predisposition or resistance to specific infections in humans

Current Opinion in Immunology

Volumn 18, Issue 4, 2006, Pages 383-390

  Picard, Capucine ^a,b   Casanova, Jean Laurent ^a,b   Abel, Laurent ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL INFECTION; BACTERIAL VIRULENCE; BIOLOGICAL TRAIT; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS; GENE DISRUPTION; GENE MUTATION; GENETIC PREDISPOSITION; GENETIC TRAIT; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNITY; IMMUNOGENETICS; INFECTION RESISTANCE; MENDELIAN TRAIT; MUTAGENESIS; MYCOBACTERIUM; NEISSERIA; NONHUMAN; NOROVIRUS; PARASITE VIRULENCE; PLASMODIUM VIVAX; REVIEW; STREPTOCOCCUS PNEUMONIAE; VIRUS INFECTION; VIRUS VIRULENCE; WART VIRUS;

GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; INFECTION; MUTATION;

EID: 33745665547     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2006.05.005     Document Type: Review

References (73)

1. Casanova J.L., and Abel L. Inborn errors of immunity to infection: the rule rather than the exception. J Exp Med 202 (2005) 197-201
2. Notarangelo L., Casanova J.L., Fischer A., Puck J., Rosen F., Seger R., and Geha R. Primary immunodeficiency diseases: an update. J Allergy Clin Immunol 114 (2004) 677-687
3. Casanova J.L., Fieschi C., Bustamante J., Reichenbach J., Remus N., von Bernuth H., and Picard C. From idiopathic infectious diseases to novel primary immunodeficiencies. J Allergy Clin Immunol 116 (2005) 426-430
4. Casanova J.L., Schurr E., Abel L., and Skamene E. Forward genetics of infectious diseases: immunological impact. Trends Immunol 23 (2002) 469-472
5. Casanova J.L., and Abel L. The human model: a genetic dissection of immunity to infection in natural conditions. Nat Rev Immunol 4 (2004) 55-66
6. Sullivan K.E., and Winkelstein J.A. Genetically determined deficiencies of the complement system. In: Ochs H., Edvard Smith C.I., and Puck J.M. (Eds). Primary immunodefiency diseases: a molecular and genetic approach (1999), Oxford University Press
7. Fijen C.A., Kuijper E.J., te Bulte M.T., Daha M.R., and Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 28 (1999) 98-105
8. Wurzner R. Deficiencies of the complement MAC II gene cluster (C6, C7, C9): is subtotal C6 deficiency of particular evolutionary benefit?. Clin Exp Immunol 133 (2003) 156-159
9. Emonts M., Hazelzet J.A., de Groot R., and Hermans P.W. Host genetic determinants of Neisseria meningitidis infections. Lancet Infect Dis 3 (2003) 565-577
10. Bathum L., Hansen H., Teisner B., Koch C., Garred P., Rasmussen K., and Wang P. Association between combined properdin and mannose-binding lectin deficiency and infection with Neisseria meningitidis. Mol Immunol 43 (2006) 473-479
11. Casanova J.L., and Abel L. Human mannose-binding lectin in immunity: friend, foe, or both?. J Exp Med 199 (2004) 1295-1299
12. Casanova J.L., and Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 20 (2002) 581-620
13. Fieschi C., Dupuis S., Catherinot E., Feinberg J., Bustamante J., Breiman A., Altare F., Baretto R., Le Deist F., Kayal S., et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med 197 (2003) 527-535
14. Dorman S.E., Picard C., Lammas D., Heyne K., van Dissel J.T., Baretto R., Rosenzweig S.D., Newport M., Levin M., Roesler J., et al. Clinical features of dominant and recessive interferon γ receptor 1 deficiencies. Lancet 364 (2004) 2113-2121
15. Vogt G., Chapgier A., Yang K., Chuzhanova N., Feinberg J., Fieschi C., Boisson-Dupuis S., Alcais A., Filipe-Santos O., Bustamante J., et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 37 (2005) 692-700. This study in two kindreds that have complete IFN-γR2 deficiency provided the description of a gain-of-glycosylation pathogenic mutation. This led to the identification of an unexpectedly high proportion of missense mutations that might cause human genetic disease by creating new N-glycosylation sites.
16. Dupuis S., Dargemont C., Fieschi C., Thomassin N., Rosenzweig S., Harris J., Holland S.M., Schreiber R.D., and Casanova J.L. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science 293 (2001) 300-303
17. Filipe-Santos O, Bustamante J, Haverkamp MH, Vinolo E, Ku CL, Puel A, Frucht DM, Christel K, von Bernuth H, Jouanguy E et al.: X-linked susceptibility to mycobacteria is caused by mutations in the NEMO leucine zipper domain that impair CD40-dependent IL-12 production. J Exp Med 2006. in press. This study provided the first genetic aetiology of X-linked recessive MSMD caused by NEMO mutations in three unrelated kindreds. The authors showed that mycobacterial susceptibility is caused by impaired IL-12 production via the CD40 pathway.
18. Frucht D.M., and Holland S.M. Defective monocyte costimulation for IFN-γ production in familial disseminated Mycobacterium avium complex infection: abnormal IL-12 regulation. J Immunol 157 (1996) 411-416
19. Picard C., Puel A., Bustamante J., Ku C.L., and Casanova J.L. Primary immunodeficiencies associated with pneumococcal disease. Curr Opin Allergy Clin Immunol 3 (2003) 451-459
20. Picard C., Puel A., Bonnet M., Ku C.L., Bustamante J., Yang K., Soudais C., Dupuis S., Feinberg J., Fieschi C., et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299 (2003) 2076-2079
21. Medvedev A.E., Lentschat A., Kuhns D.B., Blanco J.C., Salkowski C., Zhang S., Arditi M., Gallin J.I., and Vogel S.N. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 198 (2003) 521-531
22. Currie A.J., Davidson D.J., Reid G.S., Bharya S., MacDonald K.L., Devon R.S., and Speert D.P. Primary immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling. J Pediatr 144 (2004) 512-518
23. Enders A., Pannicke U., Berner R., Henneke P., Radlinger K., Schwarz K., and Ehl S. Two siblings with lethal Pneumococcal meningitis in a family with a mutation in Interleukin-1 receptor-associated kinase 4. J Pediatr 145 (2004) 698-700
24. Chapel H., Puel A., von Bernuth H., Picard C., and Casanova J.L. Shigella sonnei meningitis due to interleukin-1 receptor-associated kinase-4 deficiency: first association with a primary immune deficiency. Clin Infect Dis 40 (2005) 1227-1231
25. Yang K., Puel A., Zhang S., Eidenschenk C., Ku C.L., Casrouge A., Picard C., von Bernuth H., Senechal B., Plancoulaine S., et al. Human TLR-7-, -8-, and -9-mediated induction of IFN-α/β and -λ Is IRAK-4 dependent and redundant for protective immunity to viruses. Immunity 23 (2005) 465-478. This study explored the type I and III IFN production pathway in IRAK-4-deficient cells and showed that the human TLR-7, -8 and -9 pathway that leads to type I and III IFN production is IRAK-4-dependent but is redundant for protective immunity to viruses.
26. Cardenes M., von Bernuth H., Garcia-Saavedra A., Santiago E., Puel A., Ku C.L., Emile J.F., Picard C., Casanova J.L., Colino E., et al. Autosomal recessive Interleukin-1 receptor-associated kinase 4 deficiency in fourth-degree relatives. J Pediatr 148 (2006) 549-551
27. Takada H., Yoshikawa H., Imaizumi M., Kitamura T., Takeyama J., Kumaki S., Nomura A., and Hara T. Delayed separation of umbilical cord in two sibbling with interleukin-1 receptor associated kinase 4 deficiency: rapid screening by flow cytometer. J Pediatr 148 (2006) 546-548
28. Purtilo D.T., Cassel C.K., Yang J.P., and Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1 (1975) 935-940
29. Nichols K.E., Ma C.S., Cannons J.L., Schwartzberg P.L., and Tangye S.G. Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. Immunol Rev 203 (2005) 180-199. This is an excellent and comprehensive review about X-linked lymphoproliferative disease. This review describes the clinical and immunological features of this disorder, as well as its genetic basis.
30. Sayos J., Wu C., Morra M., Wang N., Zhang X., Allen D., van Schaik S., Notarangelo L., Geha R., Roncarolo M.G., et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 395 (1998) 462-469
31. Latour S., and Veillette A. The SAP family of adaptors in immune regulation. Semin Immunol 16 (2004) 409-419
32. Parolini S., Bottino C., Falco M., Augugliaro R., Giliani S., Franceschini R., Ochs H.D., Wolf H., Bonnefoy J.Y., Biassoni R., et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 192 (2000) 337-346
33. Sharifi R., Sinclair J.C., Gilmour K.C., Arkwright P.D., Kinnon C., Thrasher A.J., and Gaspar H.B. SAP mediates specific cytotoxic T-cell functions in X-linked lymphoproliferative disease. Blood 103 (2004) 3821-3827
34. + T cells against EBV-infected cells. Blood 105 (2005) 4383-4389. Together with [33], this study demonstrates that lack of SAP affects specific signalling pathways, resulting in severe disruption of cytotoxic T lymphocyte function in cells from XLP patients. In addition, the authors demonstrate that the SAP/2B4 pathway plays a key role in cytotoxic T lymphocyte lytic activity against EBV-positive targets by promoting the polarization of the lytic machinery.
35. + T cells. This insufficient IL-10 production might also contribute to the hypogammaglobulinaemia observed in XLP.
36. Ma C.S., Pittaluga S., Avery D.T., Hare N.J., Maric I., Klion A.D., Nichols K.E., and Tangye S.G. Selective generation of functional somatically mutated IgMCD27, but not Ig isotype-switched, memory B cells in X-linked lymphoproliferative disease. J Clin Invest 116 (2006) 322-333. This is an interesting study that describes the immunological B cell phenotype and histological organisation of the germinal centres of four XLP patients that have SAP mutations. Individuals that have XLP display defects in B cell differentiation in vivo and do not generate a normal number of isotype-switched CD27 memory B cells. These findings reveal a differential requirement for the generation of IgM and Ig isotype-switched memory B cells.
37. •], this study demonstrates that the lack of SAP affects the NKT cell development in both XLP patients and mice. This reveals a potential role of NKT cells in the immune response to EBV.
38. •].
39. Eidenschenk C., Dunne J., Jouanguy E., Fourlinnie C., Gineau L., Bacq D., McMahon C., Smith O., Casanova J.L., Abel L., et al. A novel primary immunodeficiency with specific natural-killer cell deficiency maps to the centromeric region of chromosome 8. Am J Hum Genet 78 (2006) 721-727. The authors report a novel primary immunodeficiency in which patients have specific NK cell deficiency and are susceptible to viral diseases (e.g. one patient developed an Epstein-Barr virus-driven lymphoproliferative disorder). This was discovered in a large inbred pedigree.
40. Jablonska S., and Majewski S. Epidermodysplasia verruciformis: immunological and clinical aspects. Curr Top Microbiol Immunol 186 (1994) 157-175
41. Ramoz N., Rueda L.A., Bouadjar B., Montoya L.S., Orth G., and Favre M. Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 32 (2002) 579-581
42. Tate G., Suzuki T., Kishimoto K., and Mitsuya T. Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 49 (2004) 223-225
43. Sun X.K., Chen J.F., and Xu A.E. A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 30 (2005) 573-574
44. Kurima K., Yang Y., Sorber K., and Griffith A.J. Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 82 (2003) 300-308
45. Keresztes G., Mutai H., and Heller S. TMC and EVER genes belong to a larger novel family, the TMC gene family encoding transmembrane proteins. BMC Genomics 4 (2003) 24
46. Kurima K., Peters L.M., Yang Y., Riazuddin S., Ahmed Z.M., Naz S., Arnaud D., Drury S., Mo J., Makishima T., et al. Dominant and recessive deafness caused by mutations of a novel gene, TMC1, required for cochlear hair-cell function. Nat Genet 30 (2002) 277-284
47. Laffort C., Le Deist F., Favre M., Caillat-Zucman S., Radford-Weiss I., Debre M., Fraitag S., Blanche S., Cavazzana-Calvo M., de Saint Basile G., et al. Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gammac cytokine receptor subunit or JAK-3 deficiency. Lancet 363 (2004) 2051-2054
48. Miller L.H., Mason S.J., Clyde D.F., and McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The duffy-blood-group genotype, FyFy. N Engl J Med 295 (1976) 302-304
49. Tournamille C., Colin Y., Cartron J.P., and Le Van Kim C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in duffy-negative individuals. Nat Genet 10 (1995) 224-228
50. Miller L.H., Baruch D.I., Marsh K., and Doumbo O.K. The pathogenic basis of malaria. Nature 415 (2002) 673-679
51. de Brevern A.G., Wong H., Tournamille C., Colin Y., Le Van Kim C., and Etchebest C. A structural model of a seven-transmembrane helix receptor: the duffy antigen/receptor for chemokine (DARC). Biochim Biophys Acta 1724 (2005) 288-306
52. Tournamille C., Blancher A., Le Van Kim C., Gane P., Apoil P.A., Nakamoto W., Cartron J.P., and Colin Y. Sequence, evolution and ligand binding properties of mammalian duffy antigen/receptor for chemokines. Immunogenetics 55 (2004) 682-694
53. Choe H., Moore M.J., Owens C.M., Wright P.L., Vasilieva N., Li W., Singh A.P., Shakri R., Chitnis C.E., and Farzan M. Sulphated tyrosines mediate association of chemokines and Plasmodium vivax duffy binding protein with the duffy antigen/receptor for chemokines (DARC). Mol Microbiol 55 (2005) 1413-1422. This study showed that a sulphated tyrosine residue on DARC is a key component of the interaction with P. vivax-DBL or P. knowlesi-DBL. These data are consistent with a role for tyrosine sulphation in the association of many or most chemokines with their receptors, and identify a key molecular determinant of erythrocyte invasion by P. vivax.
54. VanBuskirk K.M., Sevova E., and Adams J.H. Conserved residues in the Plasmodium vivax duffy-binding protein ligand domain are critical for erythrocyte receptor recognition. Proc Natl Acad Sci USA 101 (2004) 15754-15759
55. Hans D., Pattnaik P., Bhattacharyya A., Shakri A.R., Yazdani S.S., Sharma M., Choe H., Farzan M., and Chitnis C.E. Mapping binding residues in the Plasmodium vivax domain that binds duffy antigen during red cell invasion. Mol Microbiol 55 (2005) 1423-1434. Together with [54], this study identifies the residues in P. vivax-DBP that bind to DARC during red blood cell invasion. In particular, hydrophobic interactions were found to play a major role in the interaction of P. vivax-DBP with DARC.
56. Singh S.K., Hora R., Belrhali H., Chitnis C.E., and Sharma A. Structural basis for duffy recognition by the malaria parasite duffy-binding-like domain. Nature 439 (2006) 741-744. The authors present the crystal structure of the P. knowlesi DBL domain, which binds to DARC during invasion of human erythrocytes. They found that the residues that contact DARC and the clusters of residues under immune pressure map to opposite surfaces of the DBL, which suggests a possible mechanism of immune invasion by P. vivax.
57. Reed M.B., Caruana S.R., Batchelor A.H., Thompson J.K., Crabb B.S., and Cowman A.F. Targeted disruption of an erythrocyte binding antigen in Plasmodium falciparum is associated with a switch toward a sialic acid-independent pathway of invasion. Proc Natl Acad Sci USA 97 (2000) 7509-7514
58. Lusso P. HIV and the chemokine system: 10 years later. EMBO J 25 (2006) 447-456. This is a comprehensive review of HIV infection. It provides an update on the latest advances in our understanding of the pathogenesis of AIDS and the chemokine system, and opens up new perspectives for the development of novel treatments.
59. Stephens J.C., Reich D.E., Goldstein D.B., Shin H.D., Smith M.W., Carrington M., Winkler C., Huttley G.A., Allikmets R., Schriml L., et al. Dating the origin of the CCR5-Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet 62 (1998) 1507-1515
60. Novembre J., Galvani A.P., and Slatkin M. The geographic spread of the CCR5 Δ32 HIV-resistance allele. PLoS Biol 3 (2005) e339
61. Hummel S., Schmidt D., Kremeyer B., Herrmann B., and Oppermann M. Detection of the CCR5-Δ32 HIV resistance gene in bronze age skeletons. Genes Immun 6 (2005) 371-374
62. Sabeti P.C., Walsh E., Schaffner S.F., Varilly P., Fry B., Hutcheson H.B., Cullen M., Mikkelsen T.S., Roy J., Patterson N., et al. The case for selection at CCR5-Δ32. PLoS Biol 3 (2005) e378
63. Gonzalez E., Kulkarni H., Bolivar H., Mangano A., Sanchez R., Catano G., Nibbs R.J., Freedman B.I., Quinones M.P., Bamshad M.J., et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 307 (2005) 1434-1440. This study shows that possession of a number of copies of CCL3L1 (a ligand for the HIV coreceptor CCR5) higher than the population average is associated with protection against HIV infection and AIDS.
64. Glass W.G., McDermott D.H., Lim J.K., Lekhong S., Yu S.F., Frank W.A., Pape J., Cheshier R.C., and Murphy P.M. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203 (2006) 35-40. The authors reported an epidemiologic study in two independent cohorts of patients, and showed that CCR5-Δ32 homozygosity is strongly associated with symptomatic WNV infection.
65. -/- mice that showed that CCR5 is a crucial antiviral and survival determinant of WNV infection in mice that acts by regulating trafficking of leukocytes to the infected brain.
66. Hutson A.M., Atmar R.L., and Estes M.K. Norovirus disease: changing epidemiology and host susceptibility factors. Trends Microbiol 12 (2004) 279-287
67. Marionneau S., Ruvoen N., Le Moullac-Vaidye B., Clement M., Cailleau-Thomas A., Ruiz-Palacois G., Huang P., Jiang X., and Le Pendu J. Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology 122 (2002) 1967-1977
68. Lindesmith L., Moe C., Marionneau S., Ruvoen N., Jiang X., Lindblad L., Stewart P., LePendu J., and Baric R. Human susceptibility and resistance to Norwalk virus infection. Nat Med 9 (2003) 548-553
69. Thorven M., Grahn A., Hedlund K.O., Johansson H., Wahlfrid C., Larson G., and Svensson L. A homozygous nonsense mutation (428G→A) in the human secretor (FUT2) gene provides resistance to symptomatic norovirus (GGII) infections. J Virol 79 (2005) 15351-15355. This is an epidemiologic study that shows that the FUT2 non-secretor genotype is fully associated with resistance to symptomatic norovirus infection during nosocomial and sporadic outbreaks.
70. Lilic D. New perspectives on the immunology of chronic Mucocutaneous candidiasis. Curr Opin Infect Dis 15 (2002) 143-147
71. Dupuis S., Jouanguy E., Al-Hajjar S., Fieschi C., Al-Mohsen I.Z., Al-Jumaah S., Yang K., Chapgier A., Eidenschenk C., Eid P., et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nat Genet 33 (2003) 388-391
72. Guttman-Yassky E., Cohen A., Kra-Oz Z., Friedman-Birnbaum R., Sprecher E., Zaltzman N., Friedman E., Silbermann M., Rubin D., Linn S., et al. Familial clustering of classic Kaposi sarcoma. J Infect Dis 189 (2004) 2023-2026
73. Alcais A., Fieschi C., Abel L., and Casanova J.L. Tuberculosis in children and adults: two distinct genetic diseases. J Exp Med 202 (2005) 1617-1621. This is a review about Mendelian and complex genetic predispositions to tuberculosis reported in children and adults, respectively. It supports the hypothesis that a substantial proportion of children world-wide who have disseminated tuberculosis have a Mendelian predisposition to disease.